Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Synthetic Nucleic Acids Restore Normal Frataxin Levels in Patient-Derived Friedreich's Ataxia Cells

By LabMedica International staff writers
Posted on 02 Mar 2016
Neurological disease researchers have used synthetic nucleic acid polymers to block the defective FXN gene segment and restore normal levels of frataxin in cells derived from patients with Freidreich's ataxia.

Friedreich's ataxia is an autosomal recessive disorder that occurs when the FXN gene contains amplified repeats of the GAA (guanine-adenine-adenine) nucleotide sequence. More...
The FXN gene encodes the protein frataxin, but GAA repeat expansion causes frataxin levels to be reduced. Frataxin is an iron-binding protein responsible for forming iron-sulfur clusters. One result of frataxin deficiency is mitochondrial iron overload which can cause damage to many proteins, which can result in a variety of symptoms that include loss of muscle control, fatigue, vision or hearing impairment, slurred speech, and serious heart conditions.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) developed synthetic nucleic acids to block the effects of GAA expansion and restore normal frataxin levels.

In a paper published in the February 4, 2016, online edition of the journal Nature Communications the investigators reported that by introducing anti-GAA duplex RNAs or single-stranded locked nucleic acids into patient-derived cells, they were able to increase frataxin expression to levels similar to analogous wild-type cells. These results were considered to be significant, since synthetic nucleic acids that target GAA repeats could lead to the development of compounds for restoring curative frataxin levels. More broadly, they demonstrated a new strategy for upregulating gene expression.

"The problem arises because of a mutation within the frataxin gene (FXN) that does not code for protein. In this case, the mutation causes the synthesis of a longer piece of RNA. This longer sequence binds the DNA and gums up the works, blocking RNA production needed to produce the frataxin protein," said senior author Dr. David Corey, professor of pharmacology and biochemistry at the University of Texas Southwestern Medical Center. "The synthetic DNA or RNA prevents the mutant sequence from bending back and blocking the frataxin gene. This action activates the frataxin gene, which then makes frataxin RNA and protein at normal levels. In addition, our approach is selective for targeting the frataxin gene FXN and does not affect other genes."

Related Links:

University of Texas Southwestern Medical Center



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.